卡培他滨维持治疗晚期结直肠癌的临床疗效观察

目的 观察晚期结直肠癌应用希罗达维持化疗的疗效以及对生存时间的影响.方法 将59例晚期结直肠癌患者随机分为希罗达维持治疗组（治疗组）29例和最佳支持治疗组（对照组）30例,2组每2～3周期评价疗效,直到疾病进展.主要观察目标为近期疗效、肿瘤进展时间（TTP）及治疗组的不良反应.结果 29例患者共完成维持化疗119周期,疾病控制率为75.9％,肿瘤进展时间为5.3个月,主要不良反应为恶心呕吐、腹泻及白细胞减少,但均可忍受.结论 晚期结直肠癌患者一线化疗稳定后继续希罗达维持化疗是安全的,并能明显延长患者的肿瘤进展时间,同时不良反应均可耐受.

Clinical Effect of Maintenance Chemotherapy by Capecitabine in Advanced Colorectal Cancer

Objective To study the clinical effect and influence of survival time of maintenance chemotherapy by pemetrexed in advanced colorectal cancer. Methods Fiftynine patients of were devided in two groups randomly（29 patients in the treatment group and 30patients in the control group）. Evaluation was performed at every 2 - 3 cycles until progression of disease, short term effect , TTP and adverse reactions were observed. Results The cycles of maintenance chemotherapy were 119, control rate is 75.9 %, TTP throughout the maintenance period was 5.3 months. The main side effects were diarrhea, vomit and leucopenia which were tolerable. Conclusion Maintenance chemotherapy with Capecitabine following initial therapy is feasible. It can extend the TTP, and shows a favorable toxicity profile.